Breakthrough Therapies Raise Manufacturing Issues - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Breakthrough Therapies Raise Manufacturing Issues



FDA officials are working with drug manufacturers to ensure that accelerated development of new breakthrough therapies yields high-quality products for patients. A risk is that evaluations based on limited stability data and “provisional” specifications could mask safety issues. These challenges were discussed at the November ISPE annual meeting, along with innovative manufacturing strategies that can accelerate quality production, such as continual manufacturing systems, using a clinical manufacturing site for initial commercial production, or producing clinical supplies in a commercial site.

Sarah Miksinski, acting director of the Division of New Drug Quality Assessment 2 in the Office of New Drug Quality Assessment, emphasized the importance of manufacturers discussing such options with the agency early in development so that the agency can anticipate a filing with limited data and form an appropriate CMC review team. Early discussion of development plans also permits FDA to assess the potential manufacturing site to determine if an inspection will be needed, while also learning of any new technologies or quality-by-design approaches.  

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here